2016 News

Keyword Search
2016 | 2015 | 2014 | 2013 | 2012
Jan 13, 2016CTI BioPharma Appoints Matthew Perry To Board Of Directors
SEATTLE, Jan. 13, 2016 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that Matthew Perry, President of BVF Partners L.P. (BVF Partners) and CTI BioPharma's largest shareholder, has been appointed to the Board of Directors of CTI BioPharma. "We are pleased to welcome Matthew Perry from BVF Partners, our largest shareholder, onto our Board at this exciting stage of our company's evolution," commented James A. Bianco, M.D., CTI BioPharma's President a... 
Printer Friendly Version
Jan 11, 2016CTI BioPharma Announces Positive Progress Of Lead Clinical Programs And General Outlook For Transformational 2016
SEATTLE, Jan. 11, 2016 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced positive progress of its lead clinical program in addition to several key business priorities for 2016. "After a productive 2015, we have entered 2016 well capitalized and focused on preparing for the potential accelerated approval and launch of a new treatment option for people with intermediate and high-risk myelofibrosis with low platelet counts," said James A. Bianco, M.D., CT... 
Printer Friendly Version
Jan 05, 2016CTI BioPharma And Baxalta Complete Submission Of New Drug Application For Pacritinib For Unmet Medical Need In Myelofibrosis
SEATTLE and BANNOCKBURN, Ill., Jan. 5, 2016 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) and Baxalta Incorporated (Baxalta) (NYSE: BXLT) today announced the completion of the rolling submission of the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1 and CSF1R. CTI BioPharma and Baxalta are requesting U.S. marketing approval of pacritinib for the t... 
Printer Friendly Version